DRUG ABUSE POLICY Sample Clauses

DRUG ABUSE POLICY. The school fully supports Drug-Free Schools and Communities Act of the United States Congress. In cooperation with other agencies and organizations, we provide a program of education on the dangers of substance abuse. The program uses pamphlets, books and posters describing the effects that drugs have on physical and mental health. Advising and counseling is provided when deemed necessary as well as to those who request assistance. We make available to our students informative materials on State, Federal and local legal sanctions against drug abuse. Additionally, we provide information on counseling, treatment, and rehabilitation programs in the area.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
DRUG ABUSE POLICY. The College policy on drug abuse will be made available to employees and the Federation upon request.
Sample 1Sample 2
DRUG ABUSE POLICY. Contractor acknowledges that it has been advised and agrees to advise all its employees, subcontractors, agents, business invitees, and the employees of any subcontractor, agent, or business invitee of the following safety regulation or policy concerning illegal drugs and alcohol: It is the policy of Venoco that the use, possession, sale, transfer, purchase, or presence in one's system of illegal drugs or alcohol on Venoco property is prohibited. Entry onto Venoco property constitutes consent to an inspection of the person (including, but not limited to, the taking of a urine sample) and personal effects or property of that person, when entering or leaving Venoco property. Any person who is found in violation of the policy or who refuses to permit an inspection will be removed and barred from Venoco property, at the discretion of Venoco. All employees of contractors or sub-contractors must have passed a pre-access drug test within the last 12 months preceding the individuals first access to Venoco property. The contractor shall certify in writing a negative test result. The contractor shall not send laboratory test results. As an alternative, a contractor or sub-contractor that can show proof of an active Drug and Alcohol Testing Program or active status in a testing consortium that includes pre-employment testing and random testing at an annual rate of at least 50%, will satisfy Venoco's pre-access and random testing requirements. The contractor must certify its employees as "active" in the program.
Sample 1
DRUG ABUSE POLICY. The dangers and costs which alcohol and other chemical abuses can create in the electrical contracting industry in terms of safety and productivity are significant. The parties to this Agreement resolve to combat chemical abuse in any form and agree that, to be effective, programs to eliminate substance impairment should contain a strong rehabilitation component. The local parties recognize that the implementation of a drug and alcohol policy and program must be subject to all applicable federal, state, and local laws and regulations. Such policies and programs must also be administered in accordance with accepted scientific principles and must incorporate procedural safeguards to ensure fairness in application and protection of legitimate interests of privacy and confidentiality. To provide a drug-free workforce for the Electrical Construction Industry, each IBEW local union and NECA chapter shall implement an area-wide Substance Abuse Testing Policy. The policy shall include minimum standards as required by the IBEW and NECA. Should any of the required minimum standards fail to comply with federal, state, and/or local laws and regulations, they shall be modified by the local union and chapter to meet the requirements of those laws and regulations.
Sample 1
DRUG ABUSE POLICY. This Substance Abuse Policy has been adopted and implemented pursuant to negotiations between the Pipefitters Local No. 533 (hereinafter referred to as the "Unions") and Mechanical Contractors Association of Kansas City (hereinafter referred to as the "Association"). It is understood that Signatory Contractors shall be bound by this policy under the current Collective Bargaining Agreements. Those members are hereinafter referred to as "Contractor" or "Employer.” Should any dispute arise with respect to the application or implementation of this Policy between workers employed pursuant to the collective bargaining agreements between the Association and the Unions, such disputes shall be handled in accordance with the Joint Conference Board Procedure provisions of the Collective Bargaining Agreements.
Sample 1

Related to DRUG ABUSE POLICY

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Anti-Money Laundering/International Trade Law Compliance No Covered Entity is a Sanctioned Person. No Covered Entity, either in its own right or through any third party, (i) has any of its assets in a Sanctioned Country or in the possession, custody or control of a Sanctioned Person in violation of any Anti-Terrorism Law; (ii) does business in or with, or derives any of its income from investments in or transactions with, any Sanctioned Country or Sanctioned Person in violation of any Anti-Terrorism Law; or (iii) engages in any dealings or transactions prohibited by any Anti-Terrorism Law.

  • REGULATORY ADMINISTRATION SERVICES BNY Mellon shall provide the following regulatory administration services for each Fund and Series:  Assist the Fund in responding to SEC examination requests by providing requested documents in the possession of BNY Mellon that are on the SEC examination request list and by making employees responsible for providing services available to regulatory authorities having jurisdiction over the performance of such services as may be required or reasonably requested by such regulatory authorities;  Assist with and/or coordinate such other filings, notices and regulatory matters and other due diligence requests or requests for proposal on such terms and conditions as BNY Mellon and the applicable Fund on behalf of itself and its Series may mutually agree upon in writing from time to time; and

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!